SIMBA2 miniprotein reduces brain damage in ischemic stroke studies

Research published in the journal Cell Death & Disease has demonstrated that a miniprotein called SIMBA2 (Synthetic Interfering Mini β-Arrestin2) can reduce brain damage by up to 50% following an ischemic stroke in preclinical murine models.

Coordinated by Tiziana Borsello from the University of Milan and the Mario Negri Institute for Pharmacological Research, the molecule is designed to selectively block the JNK3 enzyme, which is involved in the neuronal death cascade triggered by cerebral ischemia. The neuroprotective effects were observed even when the treatment was administered up to three hours after the onset of ischemia, with protection remaining measurable for up to seven days.

In addition to reducing neuronal loss and preserving synapses, the study suggests that JNK3 could serve as a potential biomarker for neuronal damage, as its levels in the blood correlate with the neuroprotective efficacy of SIMBA2. While these results are currently limited to animal models, they offer a new pathway for developing therapeutic strategies for stroke recovery and sensorimotor function preservation.